Key Points
- Terry Rosen sold 28,947 shares of Arcus Biosciences on Dec. 16 at an average price of $21.88 for proceeds of $633,360, trimming his stake by 1.29% but leaving him with 2,220,553 shares valued around $48.59M.
- Stock and analyst backdrop: RCUS traded near $22 (50‑day/200‑day MAs $20.96/$14.04) and, despite a beat on quarterly EPS (-$1.27) and revenue ($26M), remains unprofitable; analysts have a consensus "Moderate Buy" with an average price target of about $28.89 (8 Buys, 2 Holds, 1 Sell).
Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) CAO Alexander Azoy sold 2,113 shares of Arcus Biosciences stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $22.16, for a total value of $46,824.08. Following the sale, the chief accounting officer directly owned 22,874 shares of the company's stock, valued at $506,887.84. This trade represents a 8.46% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Alexander Azoy also recently made the following trade(s):
- On Thursday, December 18th, Alexander Azoy sold 4,343 shares of Arcus Biosciences stock. The stock was sold at an average price of $22.25, for a total transaction of $96,631.75.
- On Tuesday, December 16th, Alexander Azoy sold 2,376 shares of Arcus Biosciences stock. The stock was sold at an average price of $21.88, for a total transaction of $51,986.88.
- On Wednesday, November 26th, Alexander Azoy sold 1,900 shares of Arcus Biosciences stock. The shares were sold at an average price of $26.00, for a total transaction of $49,400.00.
- On Monday, September 29th, Alexander Azoy sold 2,831 shares of Arcus Biosciences stock. The shares were sold at an average price of $13.00, for a total transaction of $36,803.00.
Arcus Biosciences Trading Down 1.2%
Shares of Arcus Biosciences stock opened at $22.02 on Friday. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.65 and a quick ratio of 3.65. The firm has a fifty day moving average price of $20.96 and a 200 day moving average price of $14.04. Arcus Biosciences, Inc. has a 1 year low of $6.50 and a 1 year high of $26.40. The stock has a market cap of $2.38 billion, a PE ratio of -6.40 and a beta of 0.75.
Arcus Biosciences (NYSE:RCUS - Get Free Report) last posted its quarterly earnings results on Tuesday, October 28th. The company reported ($1.27) EPS for the quarter, beating the consensus estimate of ($1.33) by $0.06. The company had revenue of $26.00 million for the quarter, compared to analyst estimates of $19.89 million. Arcus Biosciences had a negative net margin of 136.40% and a negative return on equity of 68.17%. The firm's revenue was down 45.8% on a year-over-year basis. During the same period in the prior year, the company earned ($1.00) earnings per share. Equities research analysts predict that Arcus Biosciences, Inc. will post -3.15 earnings per share for the current year.
Wall Street Analysts Forecast Growth
RCUS has been the subject of several recent research reports. Wall Street Zen upgraded Arcus Biosciences from a "sell" rating to a "hold" rating in a research report on Sunday, December 14th. UBS Group reaffirmed a "buy" rating on shares of Arcus Biosciences in a report on Monday. Bank of America increased their price target on shares of Arcus Biosciences from $17.00 to $26.00 and gave the stock a "neutral" rating in a report on Friday, November 28th. Wedbush set a $35.00 price target on shares of Arcus Biosciences and gave the company an "outperform" rating in a research report on Wednesday, October 29th. Finally, The Goldman Sachs Group increased their target price on shares of Arcus Biosciences from $14.00 to $16.00 and gave the stock a "neutral" rating in a research note on Thursday, October 30th. Eight research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Arcus Biosciences presently has an average rating of "Moderate Buy" and an average target price of $28.89.
Check Out Our Latest Research Report on Arcus Biosciences
Institutional Trading of Arcus Biosciences
A number of institutional investors and hedge funds have recently modified their holdings of RCUS. Jacobs Levy Equity Management Inc. raised its position in shares of Arcus Biosciences by 39.1% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,120,062 shares of the company's stock worth $15,233,000 after purchasing an additional 314,757 shares during the last quarter. Vestal Point Capital LP purchased a new stake in Arcus Biosciences during the 3rd quarter worth approximately $3,400,000. Public Employees Retirement System of Ohio acquired a new position in shares of Arcus Biosciences during the third quarter valued at approximately $299,000. Parkman Healthcare Partners LLC lifted its position in shares of Arcus Biosciences by 8.9% in the third quarter. Parkman Healthcare Partners LLC now owns 652,680 shares of the company's stock valued at $8,876,000 after acquiring an additional 53,070 shares in the last quarter. Finally, Decheng Capital LLC boosted its stake in shares of Arcus Biosciences by 242.3% in the third quarter. Decheng Capital LLC now owns 547,609 shares of the company's stock worth $7,447,000 after acquiring an additional 387,609 shares during the last quarter. Hedge funds and other institutional investors own 92.89% of the company's stock.
Arcus Biosciences Company Profile
(
Get Free Report)
Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
